ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q2 2025 · 201 positions · Total reported value $598.24M · Top-10 concentration 50.9% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2025 13F filing, ADAR1 Capital Management, LLC disclosed 201 equity positions with a combined reported value of $598.24M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were KROS ($71.95M), PTGX ($52.40M), BOXX ($37.99M). By sector, the heaviest allocations are Health Care 74.3%, Financials 1.5%. Versus the prior quarter, allocation shifted toward Health Care (+4.3pp) and away from Other (-4.2pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 68% of names.

The largest new positions opened in Q2 2025 were PRTA ($20.49M), SPY ($14.02M), IONS ($5.87M).

Of the 48 positions fully exited versus the prior quarter, the largest were ITCI ($6.34M), NVS ($5.57M), RCUS ($5.48M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • PRTA PROTHENA CORP PLC · $20.49M
  • SPY STATE STR SPDR S&P 500 ETF T · $14.02M
  • IONS IONIS PHARMACEUTICALS INC · $5.87M
  • VERV VERVE THERAPEUTICS INC · $5.27M
  • CRMD CORMEDIX INC · $2.16M
  • NAMS NEWAMSTERDAM PHARMA COMPANY · $2.03M
  • BPMC BLUEPRINT MEDICINES CORP · $1.92M
  • ALKS ALKERMES PLC · $1.29M

Fully Exited (vs previous quarter)

  • ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $6.34M
  • NVS NOVARTIS AG · prev qtr: $5.57M
  • RCUS ARCUS BIOSCIENCES INC · prev qtr: $5.48M
  • AVTE AEROVATE THERAPEUTICS INC · prev qtr: $3.67M
  • PTCT PTC THERAPEUTICS INC · prev qtr: $2.55M
  • CRGX CARGO THERAPEUTICS INC · prev qtr: $1.39M
  • CKPT CHECKPOINT THERAPEUTICS INC · prev qtr: $1.24M
  • AACT ARES ACQUISITION CORP II · prev qtr: $1.01M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 74.3%
Financials 1.5%
Materials 0.0%
Technology 0.0%
Other 24.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 5.39M $71.95M 12.03%
12.03%
Add
2 948.07K $52.40M 8.76%
8.76%
Add
3 337.12K $37.99M 6.35%
6.35%
Hold
4 850.44K $29.74M 4.97%
4.97%
Reduce
5 3.07M $23.50M 3.93%
3.93%
Add
6 1.94M $21.87M 3.66%
3.66%
Reduce
7 3.38M $20.49M 3.42%
3.42%
New
8 582.15K $19.23M 3.21%
3.21%
Add
9 22.68K $14.02M 2.34%
2.34%
New
10 523.22K $13.60M 2.27%
2.27%
Add
11 135.59K $12.44M 2.08%
2.08%
Hold
12 5.12M $9.99M 1.67%
1.67%
Hold
13 847.23K $8.96M 1.50%
1.50%
Add
14 2.83M $8.73M 1.46%
1.46%
Add
15 875.98K $8.60M 1.44%
1.44%
Add
16 535.07K $8.56M 1.43%
1.43%
Reduce
17 3.60M $8.21M 1.37%
1.37%
Add
18 259.50K $8.12M 1.36%
1.36%
Add
19 1.94M $8.00M 1.34%
1.34%
Add
20 750.00K $7.96M 1.33%
1.33%
Hold
21 1.21M $7.72M 1.29%
1.29%
Reduce
22 3.08M $6.99M 1.17%
1.17%
Add
23 3.01M $6.95M 1.16%
1.16%
Add
24 721.60K $6.58M 1.10%
1.10%
Reduce
25 783.22K $6.27M 1.05%
1.05%
Reduce
26 578.36K $6.03M 1.01%
1.01%
Hold
27 148.46K $5.87M 0.98%
0.98%
New
28 345.88K $5.80M 0.97%
0.97%
Reduce
29 516.48K $5.48M 0.92%
0.92%
Hold
30 469.02K $5.27M 0.88%
0.88%
New
31 134.14K $4.93M 0.82%
0.82%
Reduce
32 442.62K $4.70M 0.79%
0.79%
Reduce
33 53.34K $4.42M 0.74%
0.74%
Reduce
34 989.30K $4.41M 0.74%
0.74%
Reduce
35 302.12K $4.09M 0.68%
0.68%
Add
36 296.77K $3.90M 0.65%
0.65%
Add
37 100.97K $3.61M 0.60%
0.60%
Hold
38 915.13K $3.59M 0.60%
0.60%
Add
39 622.87K $3.38M 0.56%
0.56%
Add
40 98.03K $3.19M 0.53%
0.53%
Add
41 45.39K $2.87M 0.48%
0.48%
Add
42 28.45K $2.69M 0.45%
0.45%
Add
43 2.00M $2.49M 0.42%
0.42%
Hold
44 1.72M $2.41M 0.40%
0.40%
Add
45 170.60K $2.38M 0.40%
0.40%
Add
46 215.00K $2.20M 0.37%
0.37%
Hold
47 175.00K $2.16M 0.36%
0.36%
New
48 112.36K $2.03M 0.34%
0.34%
New
49 149.38K $2.03M 0.34%
0.34%
Hold
50 531.51K $2.01M 0.34%
0.34%
Reduce

FAQ

What did ADAR1 Capital Management, LLC buy in 2025-Q2?

In its 2025-Q2 13F filing, ADAR1 Capital Management, LLC reported 201 equity positions worth $598.24M in aggregate; its largest disclosed positions were KROS ($71.95M), PTGX ($52.40M), BOXX ($37.99M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $598.24M of long equity holdings across 201 positions as of 2025-Q2. Top-10 holdings account for 50.9% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →